SELLAS Life Sciences Group Inc SLS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
SELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026
SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
Trading Information
- Previous Close Price
- $7.88
- Day Range
- $7.15–8.04
- 52-Week Range
- $1.40–15.86
- Bid/Ask
- $7.69 / $7.74
- Shares Outstanding
- 201.95M
- Market Cap
- $1.58B
- Volume/Avg
- 587,580 / 7M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 13
Valuation
Metric | SLS |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 11.56 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
SLS
Financial Strength
Metric | SLS |
|---|---|
Quick Ratio | 18.28 |
Current Ratio | 18.83 |
Interest Coverage | — |
Quick Ratio
SLS
Profitability
Metric | SLS |
|---|---|
Return on Assets (Normalized) | −35.21% |
Return on Equity (Normalized) | −38.30% |
Return on Invested Capital (Normalized) | −41.43% |
Return on Assets
SLS
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|>Wt<tz | LOCK|@QJ^ | $138B | |||
| Moderna Inc MRNA | LOCK|$!?!z! | LOCK|W<< | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|%fLx#m? | LOCK|!X#X | $93B | |||
| argenx SE ADR ARGX | LOCK|QYdqkz | LOCK|NJ | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|ksp#mkD | LOCK|@F | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|fN!Vbn> | LOCK|@H@# | $30B | |||
| Incyte Corp INCY | LOCK|@mZl@% | LOCK|S^ | $24B | |||
| BioNTech SE ADR BNTX | LOCK|Pr@Jp!k | LOCK|Jn | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|B&%@Gns | LOCK|GTf$N | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|$!<wN$ | LOCK|xk | $15B |
United States